Brian Edward Vash

This inventor holds 18 USPTO granted patents and 29 published patent applications and 4 EPO patents, primarily in Antibody Engineering. Top assignees: Marengo Therapeutics, Inc., Novartis Ag, University of Pennsylvania. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian Edward Vash. Retrieved from https://idiyas.com/inventor/brian-edward-vash

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 29)

% Patents Active = 94.4

EPO Patents = 4 (Patent Applications = 28)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 50(Granted Patents)

Company Filing History:

12 out of 12

Marengo Therapeutics, Inc.

University of Pennsylvania

patents

4. 1 out of 1

Elstar Therapeutics, Inc.

patent

5. 1 out of 966

The University of Chicago

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Antibody Molecules

Multispecific

T Cell

Cancer Treatment

Bispecific

Calreticulin

Chimeric Antigen Receptor

Fibronectin

Lambda Light Chains

Kappa Light Chains

NKP30

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486326 - ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF (2025-12-02),

2. 12421323 - Multispecific antibody molecules comprising lambda and kappa light chains (2025-09-23),

3. 12384842 - Antibody molecules that bind to NKP30 and uses thereof (2025-08-12),

4. 12358982 - Multifunctional molecules that bind to T cell related cancer cells and uses thereof (2025-07-15),

5. 12351632 - Anti-TCR antibody molecules and uses thereof (2025-07-08),

6. 12286477 - Anti-TCR antibody molecules and uses thereof (2025-04-29),

7. 12247060 - Calreticulin binding constructs and engineered T cells for the treatment of diseases (2025-03-11),

8. 12152073 - Multifunctional molecules that bind to calreticulin and uses thereof (2024-11-26),

9. 12134654 - Multispecific molecules and uses thereof (2024-11-05),

10. 11965025 - Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules (2024-04-23),

11. 11845797 - Anti-TCR antibody molecules and uses thereof (2023-12-19),

12. 11673971 - Multispecific antibody molecules comprising lambda and kappa light chains (2023-06-13),

13. 11578130 - Regulatable chimeric antigen receptor (2023-02-14),

14. 11291721 - Multispecific and multifunctional molecules and uses thereof (2022-04-05),

15. 10287354 - Regulatable chimeric antigen receptor (2019-05-14),

Title: The Innovations and Contributions of Brian Edward Vash

Introduction: Brian Edward Vash, based in Cambridge, MA, is a significant figure in the field of biotechnology and pharmaceuticals. With a remarkable portfolio of 11 patents, he has made substantial contributions to innovations that enhance cancer treatment and therapeutic approaches through targeted molecular strategies.

Latest Patents: Among his latest innovations, Vash has developed multifunctional molecules that bind to calreticulin, designed for various applications in cancer treatment. This groundbreaking patent includes features such as an antigen binding domain that connects to a calreticulin mutant protein, immune cell engagers, cytokine modulators, and stromal modifying moieties. These advancements also encompass the encoding of nucleic acids and methodologies for producing these innovative molecules, promising new pathways for cancer therapies. Additionally, his work on multispecific molecules targets tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), showcasing his commitment to tackling cancer with novel therapeutic strategies.

Career Highlights: Brian Edward Vash has established a notable career with his roles in leading companies such as Marengo Therapeutics, Inc., and Novartis AG. His innovative research efforts have garnered attention and acclaim within the biotechnology community, further solidifying his reputation as a pioneering inventor in his field.

Collaborations: Collaboration is key in innovation, and Vash has worked alongside esteemed colleagues, including Andreas Loew and Jennifer Brogdon. These partnerships illustrate the collaborative spirit that often leads to groundbreaking advancements in technology and medicine.

Conclusion: Brian Edward Vash's contributions are vital to the landscape of cancer research and therapy. Through his inventive spirit and collaboration with industry leaders, his work continues to inspire future innovations in biotechnology, aiming to improve treatment options for patients worldwide. His patents represent not only his ingenuity but also a commitment to addressing significant health challenges through scientific advancement.

Profile summary based on public USPTO records.